NO973283L - Konjugater av terapeutisk forbindelse og fettsyre - Google Patents

Konjugater av terapeutisk forbindelse og fettsyre

Info

Publication number
NO973283L
NO973283L NO973283A NO973283A NO973283L NO 973283 L NO973283 L NO 973283L NO 973283 A NO973283 A NO 973283A NO 973283 A NO973283 A NO 973283A NO 973283 L NO973283 L NO 973283L
Authority
NO
Norway
Prior art keywords
fatty acid
therapeutic compound
acid conjugates
conjugates
therapeutic
Prior art date
Application number
NO973283A
Other languages
English (en)
Norwegian (no)
Other versions
NO973283D0 (no
Inventor
Robert George Whittaker
Veronika Judith Bender
Wayne Gerrard Reilly
Minoo Moghaddam
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN0583A external-priority patent/AUPN058395A0/en
Priority claimed from AUPN0584A external-priority patent/AUPN058495A0/en
Priority claimed from AUPN0581A external-priority patent/AUPN058195A0/en
Priority claimed from AUPN0585A external-priority patent/AUPN058595A0/en
Priority claimed from AUPN0586A external-priority patent/AUPN058695A0/en
Priority claimed from AUPN0582A external-priority patent/AUPN058295A0/en
Priority claimed from AUPN0580A external-priority patent/AUPN058095A0/en
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Publication of NO973283D0 publication Critical patent/NO973283D0/no
Publication of NO973283L publication Critical patent/NO973283L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO973283A 1995-01-16 1997-07-15 Konjugater av terapeutisk forbindelse og fettsyre NO973283L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AUPN0583A AUPN058395A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 5
AUPN0584A AUPN058495A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 6
AUPN0581A AUPN058195A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 3
AUPN0585A AUPN058595A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 7
AUPN0586A AUPN058695A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 8
AUPN0582A AUPN058295A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 4
AUPN0580A AUPN058095A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 2
PCT/AU1996/000015 WO1996022303A1 (en) 1995-01-16 1996-01-15 Therapeutic compound - fatty acid conjugates

Publications (2)

Publication Number Publication Date
NO973283D0 NO973283D0 (no) 1997-07-15
NO973283L true NO973283L (no) 1997-09-08

Family

ID=27560724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973283A NO973283L (no) 1995-01-16 1997-07-15 Konjugater av terapeutisk forbindelse og fettsyre

Country Status (10)

Country Link
US (3) US5952499A (de)
EP (1) EP0804459A4 (de)
JP (1) JPH11502509A (de)
BR (1) BR9607492A (de)
CA (1) CA2210500A1 (de)
FI (1) FI973002L (de)
NO (1) NO973283L (de)
NZ (1) NZ298712A (de)
RU (1) RU2166512C2 (de)
WO (1) WO1996022303A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
EE200100123A (et) * 1998-08-31 2002-06-17 Biogen, Incorporated CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
AUPP751398A0 (en) * 1998-12-04 1999-01-07 Commonwealth Scientific And Industrial Research Organisation Methotrexate derivatives
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
MXPA01012206A (es) * 1999-05-24 2002-06-21 Sankyo Co Composiciones farmaceuticas que contienen anticuerpo anti-fas.
GB9930026D0 (en) * 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (de) * 2001-03-23 2005-05-11 Luitpold Pharm Inc Fettamin-arzneimittel-konjugate
JP4814486B2 (ja) * 2001-06-05 2011-11-16 シヴィダ・インコーポレイテッド 持続放出性鎮痛性化合物
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EA008864B1 (ru) * 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
KR20080082976A (ko) * 2005-12-16 2008-09-12 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 서브-미크론 표면 플라즈몬 공진 센서 시스템들
DE102006035083A1 (de) * 2006-07-28 2008-01-31 medac Gesellschaft für klinische Spezialgeräte mbH Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8710069B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-nornicotine codrugs combinations for pain management
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110178024A1 (en) 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
US20100240883A1 (en) * 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
DK2531221T3 (da) 2010-02-03 2019-06-17 Nanopet Pharma Gmbh Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
RU2683274C2 (ru) 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
EP3394080B1 (de) * 2015-12-23 2023-06-07 The University Of British Columbia Lipid-verknüpfte prodrugs
EP3634978A1 (de) 2017-06-07 2020-04-15 Adrx, Inc. Tau-aggregationshemmer
EP3668886A2 (de) 2017-08-18 2020-06-24 Adrx, Inc. Peptidinhibitoren der tau-aggregation
RU2713838C1 (ru) * 2019-04-23 2020-02-07 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ анестезиологического обеспечения при селективной доставке химиопрепарата к сетчатке глаза при лечении интраокулярной ретинобластомы у детей

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
DE3904119A1 (de) * 1989-02-11 1990-08-16 Hoechst Ag Polymerfixiertes methotrexat, verfahren zur herstellung und verwendung
US5583198A (en) * 1989-12-22 1996-12-10 Commonwealth Scientific And Industrial Research Organization Amino acids, peptides or derivatives thereof coupled to fats
DK0506748T3 (da) * 1989-12-22 1996-01-22 Commw Scient Ind Res Org Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
JPH0421694A (ja) * 1990-05-16 1992-01-24 Asahi Chem Ind Co Ltd 新規なヌクレオシド―リン脂質複合体
EP0576605A4 (en) * 1991-03-19 1994-06-08 Vithal J Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
DE69230855D1 (de) * 1991-07-26 2000-05-04 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
DE4310516A1 (de) * 1993-02-09 1994-08-11 Boehringer Mannheim Gmbh Lipoprotein (a)-Peptide und deren Verwendung
DE4311987A1 (de) * 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
CA2167818A1 (en) * 1993-08-02 1995-02-09 Robert George Whittaker Therapeutic compound - fatty acid conjugates

Also Published As

Publication number Publication date
CA2210500A1 (en) 1996-07-25
WO1996022303A1 (en) 1996-07-25
EP0804459A1 (de) 1997-11-05
BR9607492A (pt) 1999-06-29
FI973002A7 (fi) 1997-08-19
FI973002L (fi) 1997-08-19
US20030023104A1 (en) 2003-01-30
US5952499A (en) 1999-09-14
EP0804459A4 (de) 1999-05-26
NO973283D0 (no) 1997-07-15
JPH11502509A (ja) 1999-03-02
US6281376B1 (en) 2001-08-28
FI973002A0 (fi) 1997-07-15
RU2166512C2 (ru) 2001-05-10
NZ298712A (en) 1998-12-23

Similar Documents

Publication Publication Date Title
NO973283L (no) Konjugater av terapeutisk forbindelse og fettsyre
BR9602637A (pt) Cateter
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FI950910A7 (fi) Rasvahappojohdannaiset
IS4644A (is) Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra
EP0765166A4 (de) Radioaktivmarkierte annexin-galaktose konjugate
KR970000228A (ko) S-에토돌락의 경구용 제제
FI950909A7 (fi) Rasvahappojohdannaisia
DE69606053D1 (de) Modifizierte fluorsulfonsäure
DE59608428D1 (de) Ballenpresse
IT1276799B1 (it) Formulazioni di f-silicone
ITMI941169A0 (it) Formulazioni farmaceutiche
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
EP0837863A4 (de) Dinatriumalendronat-formulierungen
FI970195L (fi) Trifluormetyylikinoliinikarboksyylihappojohdannainen
DE59610423D1 (de) Partikulare arzneiform
BR9606066A (pt) Composto e formulação farmacêutica
DE69619022D1 (de) Ballenpresse
EE9700123A (et) Välispidiselt kasutatav põletikuvastane vahend
KR970000226A (ko) S-이부프로펜의 경구용 제형
KR970041939U (ko) 부품의 방진체결구조
DE69623690D1 (de) Ballenpresse
SE9502453D0 (sv) Drug formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application